Published in Vaccine Weekly, August 2nd, 2006
According to a study from Italy, "Double transgenic mice overexpressing the transforming rat HER-2/neu oncogene and the mutated p53, with both dominant-negative and a gain-of-function properties, display early aggressive and metastasizing parotid tumors. Multiple acinar and ductal hyperplasia foci overexpressing the HER-21neu gene product are evident at week 5 and progress to poorly differentiated carcinoma by week 7. Mice die before week 18 with invasive carcinomas and multiple metastases that no longer...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.